19/10/2026 US FDA approved Jemperli for MSI-H/dMMR locally advanced Rectal Cancer Quanta Therapeutics receives US FDA Fast Track Designation for QTX3034 in KRAS G12D-mutated CRC US FDA accepts UroGen's UGN-103 NDA for recurrent LG-IR-NMIBC, with PDUFA date on June 14, 2027 US FDA approved Jemperli for MSI-H/dMMR locally advanced Rectal Cancer (Ref) GSK announced US FDA approval of Jemperli (dostarlimab; anti-PD-1) as the first and only immunotherapy for adults with MSI-H/dMMR